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Curcumin is one of the promising natural products extracted from the rhizomes of curcuma longa and has
been extensively investigated by researchers to explore its potential as a chemopreventive and therapeutic
agent against several chronic diseases. To further enhance the cytotoxic potential of curcumin, its derivative
(2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone (BHMC) has been synthesized and
investigated, and its antitumor eﬀect on tested on 4T1 challenged mice. BHMC was recorded with in
vitro cytotoxicity on murine 4T1 breast cancer cells with IC50 value 13.66 mM, which was 2 times lower
than curcumin after 72 hours of treatment. An in vivo study indicated that BHMC possessed antitumor
eﬀect on the 4T1 cells of the challenged mice by induction of apoptosis, antiproliferation, anti-
inﬂammation and antimetastasis. This eﬀect is better compared to curcumin treatment at the same
evaluated concentration. Thus, BHMC is a potential antitumor agent against breast cancer.1. Introduction
Cancer is still among the leading causes of death worldwide
with breast cancer as the primary cancer incidence for women.1
Triple negative breast cancer (TNBC) is the subtype of breast
cancer with absence of estrogen receptor, progesterone receptor
and human epidermal growth factor receptor 2 (HER2). TNBC is
highly aggressive associated with high event of relapse, metas-
tasis and poor survival. Chemotherapy is the common strategy
among the limited treatment options for TNBC. However, TNBC
may possess resistance against standard chemotherapeutic
drugs such as anthracycline and taxane if they have been
previously used as adjuvant or neoadjuvant. Thus, there isMalaysia, Serdang, Selangor, Malaysia.
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hemistry 2017a need to discover potential treatment for TNBC.2 Natural
compound has been proposed as safe and potential agent
against TNBC.3 Among the natural compounds, curcumin that
present in the spice turmeric has been reported with antitumor
eﬀect on TNBC.4,5 Resolving cancer challenged by natural
product hold better potential with the introduction of chemical
synthesis, which resolve the availability of the compounds of
interest.6 On the other hand, synthetic compounds also help to
improve the drug sensitivity and specicity while reduce the
toxicity via chemical modication.7
Curcumin (Fig. 1A) is one of the classical natural product
extracted from the rhizomes of Curcuma longa (turmeric) and
named it curcumin.8 Curcumin mainly identied asFig. 1 The chemical structures of (A) curcumin and (B) 2,6-bis-(4-
hydroxy-3-methoxybenzylidene)cyclohexanone (BHMC).
RSC Adv., 2017, 7, 36185–36192 | 36185
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View Article Onlineantioxidant, anti-inammatory,9–12 anti-cancer9,13–17 and anti-
acetylcholinesterase18 activities. Several biological activities
including the hepato- and nephro-protective,19–22 thrombosis
suppressing,23 myocardial infarction protective,24,25 curcumin
has proved to be potential candidate for future drug discovery.
In spite of several pharmacological properties, curcumin that
was classied under “pans-assay interference compounds” and
“invalid metabolic panaceas” still facing several liabilities
including instability, poor solubility, poor selectivity and
multiple modes of assay interference particularly to the in vitro
based assays.26,27 Thus, more eﬀorts to improve eﬃcacy, selec-
tivity of curcumin are needed. In recent years, chemical modi-
cation of curcuminoids has been increasingly investigated. For
example, various curcumin analogues have been reported with
enhance antitumor eﬀect than curcumin.28 A curcumin deriva-
tive, 2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone
(BHMC) (Fig. 1B) has been synthesised with diketone moiety
of curcumin has been replaced with mono cyclic ketone. To
avoid false positive results contributed by the assay interference
character of curcumin, in vivo validation are especially on those
potential curcumin analog.27 This synthetic curcuminoid
analogue has been reported with antinociceptive eﬀect in mice
through inhibition of various inammatory mediators.29–31
Inammation has been correlated with progression of triple
negative breast cancer including promotion of cancer cells
invasion and migration.32 The anti-inammatory eﬀect of
BHMC has been evaluated in vitro29 and in vivo.30 BHMC has
been reported with cytotoxic eﬀect on estrogen dependent MCF-
7 cells.33 In addition, BHMC was reported with greater in vitro
cytotoxic eﬀect than curcumin to TNBC MDA-MB-231 cells.34
However, the in vivo antitumor eﬀect of BHMC particularly on
TNBC was not evaluated. 4T1 has been reported as excellent
model system for TNBC study as its physical location, prolifer-
ative, metastatic and inammatory characteristics mimic
human TNBC.32,35 In this study, 2,6-bis(4-hydroxy-3-
methoxybenzylidene)cyclohexanone (BHMC) was synthesized
and its antitumor eﬀect was compared with curcumin using in
vivo 4T1 mouse model.
2. Materials and methods
2.1. Synthesis of BHMC
Curcumin (C7727) was purchased from Sigma-Aldrich (USA).
BHMC was chemically synthesized from 4-hydroxy-3-
methoxybenzaldehyde (cyclohexanone). Briey, a mixture of 3-
methoxy-4-hydroxy (vanillin) (40 mmol, 2 equiv.) and cyclohex-
anone (20 mmol, 1 equiv.) was dissolved in 25 mL of absolute
ethanol. Themixture was heated at 50 C for half hour and conc.
HCl (2.0 mL) was added drop wise over 5 min to the stirred
mixture. The mixture was further stirred for one hours and le
over night in refrigerator. Themixture was dissolved in ice water
(500 mL) and transferred into separating funnel. A yellow
viscous product was oating on the surface of water, which was
extracted with ethyl acetate (250 mL  3 times). The ethyl
acetate layer was collected, dried over rotary evaporator and
then pass to sodium sulphate anhydrous. The crude product
was subjected to further purication by silica gel column36186 | RSC Adv., 2017, 7, 36185–36192chromatography. The column was eluted with ethyl acetate and
hexane (40 : 60%). Yield 76%; yellow powder, UV (CHCI3): lmax
302, 339 nm; IR (CHCI3 cm
1): nmax 3393 (OH), 2928 (Ar-C–H)
1618 (C]O), 1527 (Ar C]C str.); 1H-NMR (600 MHz, CDCI3):
d in ppm: 7.78 (bs, 2H, –C]C–H), 7.12 (dd, 2H, J¼ 8.34, 1.92 Hz,
H-60, H-600), 7.02 (d, 2H, J ¼ 1.92 Hz, H-20, H-200), 6.90 (d, 2H, J ¼
7.90 Hz, J ¼ 8.34, H-50, H-500), 3.91 (s, 6H, 2  OCH3, C-30, C-300),
2.90 (m, 4H, H-3, H-5), 1.82 (m, 2H, H-4). 13C-NMR (150 MHz,
CDCI3) d in ppm: 190.41, (C]O), 151.89 (C-40, C-400), 149.71 (C-
30, 300), 136.83, (–C]C–H), 134.80 (C-2, 6), 132.23 (C-10, 100)
128.36, (C-60, 600, 20, 200), 115.34, (C-50, 500), (56.07, OCH3), 28.74,
(C-3, C-5), (23.42, C-4). MS: m/z ¼ 366 (100%) [M]+, EI-MS m/z
(rel. int.) 351 (56), 335 (68). 321 (17), 309 (12), 161 (24), 131 (15).
HR-EIMS C22H22O5. 366.231 calc. for 366.229.
The purity of compound was determined by using JASCO-
HPLC attached with ChromNAV-soware (JASCO Corporation,
Tokyo, Japan). The column used XBridge RP-18 (5 mm particle
size, 4.6  150 mm i.d.; Waters Corporation, Wexford, Ireland)
kept at ambient temperature. Injection volume of 20 mL, ow
rate at 1mLmin1. and detector wavelength was adjusted at 250
and 366 nm, mobile phase H2O and MeOH (40 : 60), retention
time (tR) 11.66 min. The percentage of purity was determined by
calculating the peak purity method automatically.362.2. In vitro cell viability assay
Murine 4T1 TNBC cells were purchased from American Type
Culture Collection and cultured in RPMI-1640 medium (Sigma-
Aldrich, USA) supplemented with 10% Fetal Bovine Serum (FBS)
(Gibco, Thermo Fisher Scientic, USA) at 37 C, 5% CO2. Cell
viability was determined by MTT assay where 4T1 cells were
seeded (0.8  105 cells per mL) in 96 well plate overnight. Then,
BHMC and curcumin (Sigma-Aldrich, USA) were added to the
cells at concentration ranging within 30–0.47 mg mL1 by two
fold serial dilution and further incubated at 37 C, 5% CO2 for
24, 48 or 72 hours. Aer the incubation time, MTT solution
(5 mgmL1) was added into all wells and further incubated for 4
hours. The purple formazon formed was then dissolved by 100
mL of DMSO (Sigma-Aldrich, USA) and the absorbance was
measured at 570 nm using mQuant plate reader (Bio-Tek
Instrument, USA). Cell viability was calculated as below:
Cell viability (%) ¼ (absorbance of treated well)/
(absorbance of control well)  100%
IC50 (concentration that reduce 50% of cell viability
comparing to untreated cells) was obtained from the graph of
cell viability vs. concentration.2.3. In vivo antitumor eﬀect of BHMC
Female mice (n ¼ 18, 6 weeks old) were purchased from
Comparative Medicine and Technology Unit (COMeT), Institute
of Bioscience, Universiti Putra Malaysia. The mice were fed with
distilled water and standard pellets ad libitum at room
temperature and 12 hours of day/dark light cycles. This study
was conducted according to the guidelines and was approved byThis journal is © The Royal Society of Chemistry 2017
Table 1 IC50 value (mM) of BHMC and curcumin on murine 4T1 breast
cancer cells
24 h 48 h 72 h
BHMC (mM) 54.64  2.33 21.66  2.66 13.66  3.24
Curcumin (mM) 81.44  2.44 48.86  3.46 27.15  2.36
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View Article OnlineInstitution of Animal Care and Use Committee (IACUC), Uni-
versiti Putra Malaysia (UPM/IACUC/AUP-R009/2015). All animal
experiment was carried out in accordance with the Malaysia
Animals Act 1953 (Revised-2006) under Malaysian Veterinary
Council (MVC) for animal experiments.
Aer 2 weeks of acclimatization of mice (body weight22 g),
mice were separated into 3 groups and challenged with 1  105
4T1 cells per mice subcutaneously. BHMC and curcumin were
dissolved in olive oil. Untreated mice (n ¼ 6) were fed with olive
oil, curcumin 50 mice were orally fed with 50 mg kg1 body
weight (BW) of curcumin (Sigma-Aldrich, USA) and BHMC 50
mice were orally fed with 50 mg kg1 BW of BHMC for 28 days.
Throughout the experiment period, tumors were measured
using a caliper and the tumor volumes were calculated by the
following formula:
Tumor volume ¼ (d2  a)/2
d ¼ tumor measurement at the widest point a ¼ tumor
dimension at the longest point.
Aer the 28 days of treatment, mice were amnestied with
isourane, and euthanised by cervical dislocation. Serum, lung
and tumor were collected and subjected to the following assays.
Tumor per body weight ratio was calculated.
2.4. Hematoxylin and eosin (H&E) histology analysis of
tumor
Harvested tumor was xed in 10% formalin, embedded in
paraﬃn, section and stained with H&E. Histology of the tumor
was viewed under bright-eld microscope (Nikon, Japan). Even
of mitotic cells were counted from ve random elds of the
slides.
2.5. Lung clonogenic assay
Lung was harvested, washed with ice-cold PBS, minced, treated
with 2 mg mL1 collagenase type IV for 1 hour at 37 C and
ltered through 70 mmstrainer. Then, the ltrate was pelleted at
2000 rpm for 5 minutes. The lung pellet was cultured in 10 mL
of RPMI-1640 supplemented with 10% Fetal Bovine Serum (FBS)
(Gibco, Thermo Fisher Scientic, USA) at 37 C, 5% CO2 for 10
days. Aer the incubation period, all wells were xed with
methanol for 1 hour and stained with 0.5% crystal violet for 2
hours. Number of colonies formed per organ was counted for
untreated, curcumin treated and BHMC treated groups.
2.6. Expression of MMP9, TNF-a, IL-1b, IL-4, G-CSF and NF-
kB in tumor by quantitative reverse transcription PCR (RT-
qPCR)
Total RNA from the tumor was extracted using RNeasy mini kit
(Qiagen, USA) according to the manufacturer's protocol. cDNA
was synthesized from 1 mg of total RNA using NEXscript cDNA
synthesis kit (NEX Diagnostics, Korea) according to the manu-
facturer's protocols. Primers for target genes MMP9, TNF-a, IL-
1b, IL-4, G-CSF, NF-kB and house-keeping gene b-actin were
listed in Table 2. Evaluation of primer eﬃciency and expression
of the targeted genes were performed using NEXpro qPCRThis journal is © The Royal Society of Chemistry 2017Evagreen Master Mix (NEX Diagnostics, Korea) using Eco Real
Time PCR system (Illumina, USA) by the following steps: 95 C
for 2 min, 40 cycles of 95 C for 10 s, 60 C for 45 s and acqui-
sition of uorescent signal. Expression of the targeted genes in
the samples were normalized by b-actin and the fold change in
the expression of each target gene was calculated by the Eco 48
Soware (Illumina, USA) using the eﬃciency-corrected method.
2.7. Serum IL-1b and TNF-a levels
IL-1b and TNF-a cytokines level in the serum were measured by
ELISA kits (R&D system, USA) according to the manufacturer's
protocol.
2.8. Secondary tumor regeneration
Tumor was harvested and dissociated using accutase (Innova-
tive Cell Tech, USA). Mice (n ¼ 10, 8 weeks old) were separated
into two groups. All mice were injected subcutaneously with 1
106 cells harvested from untreated tumor in the lower le
abdomen. On the other hand, mice in group 1 and 2 were
injected subcutaneously with 1  106 cells harvested from the
tumor of curcumin 50 mg kg1 BWmice and BHMC 50 mg kg1
BW tumor in the lower right abdomen, respectively. Tumor
progression was then observed for 21 days.
3. Results
3.1. In vitro cytotoxicity of BHMC on 4T1 cells
BHMC was prepared as previously described.31 The in vitro
cytotoxicity of BHMC was compared with curcumin on 4T1 cells
by MTT assay. As shown in Table 1, both BHMC and curcumin
were cytotoxic to 4T1 cells in time dependent manner where the
IC50 value of both treatment reduced from 24 to 72 hours. More
interestingly, IC50 value of BHMC at 48 and 72 hours were
approximately 2 folds lower than curcumin on 4T1 cells.
3.2. In vivo antitumor eﬀect of BHMC on 4T1 challenged
mice
To evaluate the antitumor eﬀect of BHMC on breast cancer,
mice challenged with 4T1 breast cancer cells were subjected to
50 mg kg1 BW of curcumin or BHMC treatment. Tumor start to
observe at day 5 in untreated mice post-inoculation of 4T1 cells.
Both curcumin and BHMC treated mice were observed with 5
and 9 days delay of tumor formation comparing to the
untreated mice (Fig. 2A). Aer 28 days of treatment, without
changes of the body weight were observed in all the mice
(Fig. 2B), tumor burden of curcumin and BHMC treated mice
were 1.86 and 3.10 folds smaller than the untreated mice
(Fig. 2C and D). Based on the histology analysis, tumorRSC Adv., 2017, 7, 36185–36192 | 36187
Fig. 2 (A) Tumor volume change; (B) body weight change; (C) representative image of tumor harvested (D) tumor/BW ratio of untreated,
curcumin 50mg kg1 BWmice and BHMC 50mg kg1 BW 4T1 challenged mice. Signiﬁcant values were calculated against untreated group (*P <
0.05).
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View Article Onlineharvested from untreated mice was observed with highest
number mitotic cells. On the other hand, curcumin and BHMC
treatedmice were recorded with 1.67 and 3.75 folds less number
of mitotic cells in the tumor (Fig. 3), which indicated that lower
tumor burden in the curcumin and BHMC treated mice maybe
contributed by anti-proliferation eﬀect. In addition, clonogenic
assay has shown that high number of 4T1 breast cancer cells
have metastasized to lung in the untreated mice. On the other
hand, mice treated with curcumin and BHMC were observed
with lower event of 4T1 metastasis into lung indicating that
both treatment possess anti-metastasis eﬀect (Fig. 4). Overall,
antitumor eﬀect of BHMC was better comparing to curcumin as
the BHMC treated mice was recorded with lower tumor burden
(Fig. 2), mitotic cells in the tumor (Fig. 3) and lung metastasis
(Fig. 4) comparing to the curcumin treated mice.
To understand the regulation of inammation and metas-
tasis related genes by both curcumin and BHMC treatment,
which contribute to the delay of tumor progression, expressionFig. 3 (A) Histological staining of the tumor. Red circles indicate mitotic
calculated against untreated group (*P < 0.05).
36188 | RSC Adv., 2017, 7, 36185–36192of MMP9, TNF-a, IL-1b, IL-4, G-CSF and NF-kB genes in the
tumor of untreated, curcumin 50 and BHMC 50 treated mice
were evaluated by RT-qPCR (Fig. 5). BHMC treatment was able
to suppress expression of MMP9, TNF-a, IL-1b, IL-4, G-CSF and
NF-kB genes comparing to the untreated mice. On the other
hand, curcumin treated was able to suppress expression of TNF-
a, IL-1b, IL-4, G-CSF and NF-kB genes comparing to the
untreated mice. However, expression of MMP9 was not signi-
cantly regulated by curcumin treatment (Fig. 5). Level of IL-1b
and TNF-a were further validated by checking serum IL-1b and
TNF-a by ELISA. Both curcumin and BHMC treatment were able
to reduce the serum level of IL-1b and TNF-a comparing to the
untreated mice (Fig. 6).
Furthermore, regeneration capacity of the tumor harvested
from untreated and curcumin or BHMC treated mice were
evaluated by transplanting 1 million cells to healthy mice.
When injected with tumor cells harvested from untreated and
BHMC treated 4T1 challenged mice, tumor/BW ratio generatedcells. (B) Numbers of mitotic cells per groups. Signiﬁcant values were
This journal is © The Royal Society of Chemistry 2017
Fig. 4 RT-qPCR analysis on expression of MMP9, TNF-a, IL-1b, IL-4,
G-CSF and NF-kB genes in the tumor of untreated, curcumin 50 mg
kg1 BWmice and BHMC 50mg kg1 BW 4T1 challengedmice. Results
were indicated in the b-actin normalized fold changes comparing to
the untreated control. Fold changes >2 were indicated as signiﬁcant.
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View Article Onlinefrom the untreated tumor cells was approximate 2.8 fold higher
than the tumor generated from BHMC group. On the other
hand, tumor generated from curcumin treated mice was only
1.25 fold lower than tumor generated from the untreated mice
(Fig. 7).4. Discussion
Prognosis of TNBC remains poor in spite of advance in under-
standing of breast cancer pathologic features and molecular
characteristics.37 TNBC are more diﬃcult to treat as they carry
fewer targets and generally develop resistant to conventional
chemotherapeutic agents.38 Thus, there is a need to continue
the discovery of novel eﬀective cytotoxic agents against TNBC
with minimum or no toxic side eﬀect. Curcumin is a polyphenol
presents in the turmeric Curcumina longa. It belongs to the 1,3-Fig. 5 Serum IL-1b and TNF-a level of untreated, curcumin 50 mg
kg1 BW mice and BHMC 50 mg kg1 BW 4T1 challenged mice.
Signiﬁcant values were calculated against untreated group (*P < 0.05).
This journal is © The Royal Society of Chemistry 2017dicarbonyl or b-diketone class of compounds, which possess
several biological activities including important building blocks
for the synthesis of core heterocycles such as pyrazole, iso-
xazole, and triazole in medicinal chemistry.39 Curcumin has
been identied as strong anti-inammatory agents that has
broad spectrum of antitumor activity.35 Structure activity rela-
tionship of curcumin and its analogous is well established in
the literatures.40,41 Curcumin was reported as potential agents
targeting TNBC as recent study has reported that it was more
sensitive to human TNBC MDA-MB-231 cells than human
estrogen dependent MCF-7 breast cancer cells.42 A part of
interesting biological activities, still curcumin not recom-
mended for therapeutic potential because of low bioavail-
ability.26,27 Therefore, there is need to modify its structure to
improve the bioavailability, stability and selectivity. Recent
study further support the idea that synthetic chemistry help to
enhance the eﬃcacy and safety of known natural metabolites.43
For examples, curcumin analogues were reported with enhance
cytotoxicity on various types of cancer cells.28,44 In this study,
BHMC that is the analog of curcumin was synthesized. Previ-
ously, the antinociceptive activity31 and anti-inammatory
eﬀect29,30 of BHMC were evaluated. Unlike curcumin that
contain enol moiety, BHMC possessing a,b-unsaturated bis-
enone system which is an essential for the several biological
activities including anticancer eﬀect as in chalcones and bis-
chalcones.41 Such compounds with conjugated enones or
enone-like compounds exhibited potential interaction with
Michael acceptor can react selectively with target nucleo-
philes.41 This structure may contributed to the greater cytotoxic
eﬀect of BHMC on 4T1 cells in vitro, which was similar to the
previous in vitro studies on human TBNC MDA-MB-231 cells.34
In addition, in vivo antitumor eﬀect of BHMC was compared
with curcumin using mouse 4T1 model. Mice challenged with
4T1 has been used as in vivo model to evaluate antitumor and
antimetastasis eﬀect of chemicals on TNBC.45,46 In this study,
untreated mice was recorded with tumor development on day 3
post challenged. In addition, high tumor mitotic event and lung
metastasis were observed too. On the other hand, both curcu-
min and BHMC treatment were found with delayed tumor
formation. Curcumin was reported to suppress cellFig. 6 Representative images and bar chart of the colonies formed in
lung of untreated, curcumin 50 mg kg1 BW mice and BHMC 50 mg
kg1 BW 4T1 challenged mice. Signiﬁcant values were calculated
against untreated group (*P < 0.05).
RSC Adv., 2017, 7, 36185–36192 | 36189
Fig. 7 Tumor/BW ratio of mice transplanted with 1  106 cells harvested from untreated tumor in the lower left abdomen and 1  106 cells
harvested from curcumin 50 mg kg1 BW mice or BHMC 50 mg kg1 BW tumor in the lower right abdomen. Signiﬁcant values were calculated
against untreated group (*P < 0.05).
Table 2 Primer sequences for qRT-PCR gene expression study
Gene
Primer sequence (50–30)
Forward Reverse
MMP9 GTCTTCCTGGGCAAGCAGTA CTGGACAGAAACCCCACTTC
TNF-a CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC
IL-1b CGCCAATGACTCAGAGGAAGA AGGGCGTCATTCAGGATGAA
IL-4 AGATGGATGTGCCAAACGTCCTCA AATATGCGAAGCACCTTGGAAGCC
G-CSF CTCAGAAATGTTTGACCTCCAG TGACAAGCAGAAAGTCCTTCAG
NF-kB GTG CGTCTGGCCTGGTAAG CCCAGGATGTG TACTCAGAGC
b-Actin TCCTTCCTGGGCATGGAG AGGAGGAGCAATGATCTTGATCTT
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View Article Onlineproliferation of TNBC in vitro.47 Lower number of mitotic cells
observed in the tumor of curcumin and BHMC treated mice
supported the report on the in vitro antiproliferation eﬀect and
given the idea that lower tumor burden in the treated mice
maybe contributed by the inhibition of 4T1 cells proliferation.
The antiproliferative eﬀect of BHMC has been correlated to its
interactions with nuclear type II sites.33
TNBC is a type of highly metastatic cancer.48 Inammation
was found to promote tumor cell proliferation and expression of
MMP9 that support the cancer metastasis.49 Curcumin has been
reported with in vitro antimetastatic eﬀect on breast cancer via
suppression of MMP-9 (ref. 50) and suppression of inamma-
tion.51 In this study, both curcumin and BHMC were found with
lower lung metastasis comparing to untreated mice. This anti-
metastatic eﬀect maybe contributed by the suppression of
inammatory and MMP9 as observed in the gene expression
study. Although both curcumin and BHMC show similar inhi-
bition on inammatory related genes, signicant suppression
of MMP9 expression by BHMC may contribute to its better
antimetastatic eﬀect than curcumin. Previous study has shown
that curcumin possessed substantial antitumor and antimeta-
stasis when treated at 800 mg kg1 BW.35 Encapsulation of
curcumin with dendrosome help to reduce the eﬀective dosage36190 | RSC Adv., 2017, 7, 36185–36192to 40 mg kg1 BW.52 In addition, TNBC was also known with
high rate of recurrence.48 In this study, recurrence of untreated
tumor with tumor harvested from curcumin or BHMC treat-
ment were compared by injected them in the secondary healthy
mice. Aer 21 days of secondary challenge, tumor burden
originated from BHMC treated mice were remain lowest
comparing those from untreated or curcumin treated mice.
This result indicate that BHMC may even help to delay recur-
rence of TNBC even better than curcumin.5. Conclusions
This study reported that the synthesis BHMC, which is an
analogue of curcumin showed better in vitro cytotoxicity and in
vivo antitumor eﬀect on 4T1 TNBC model than curcumin via
suppression of inammation, cancer cells proliferation and
metastasis.Conﬂict of interest
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